Pauline Yeo

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Veronica Novotny‐Diermayr, Kanda Sangthongpitag, Chang Hu et al. · Molecular Cancer Therapeutics · 2010 · 132 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease

Steven D. Linton, Teresa Aja, Robert A. Armstrong et al. · Journal of Medicinal Chemistry · 2005 · 106 citations

Life Sciences, Pharmacokinetics, Pharmacology +14

Discovery of (2<i>E</i>)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1<i>H</i>-benzimidazol-5-yl}-<i>N</i>-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile

Haishan Wang, Niefang Yu, Dizhong Chen et al. · Journal of Medicinal Chemistry · 2011 · 91 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

InP/GaAsSb/InP double HBTs: a new alternative for InP-based DHBTs

C. R. Bolognesi, Miroslav Dvořák, Pauline Yeo et al. · IEEE Transactions on Electron Devices · 2001 · 73 citations

Engineering, Electrical Engineering, Physics +17

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

Jenny G. Low, Lawrence Lee, Eng Eong Ooi et al. · Vaccine · 2014 · 69 citations

Veterinary Medicine, Immunology, Infectious Diseases +17